Personalized briefing
Discovery of the day · Neurology
[Series] Fluid biomarkers in the evolving care landscape of Alzheimer’s disease and related disorders
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Fluid biomarkers for Alzheimer’s disease and related disorders have advanced rapidly through ultrasensitive and multiplexing technologies and high-specificity antibodies, enabling blood-based assays to enter routine clinical use. Blood-based biomarkers such as neurofilament light for frontotemporal dementia and amyotrophic lateral sclerosis, and phosphorylated tau 217 for Alzheimer’s disease diagnosis, are now being implemented in clinical practice alongside the increasing availability of amyloid-targeting treatments. For your work bridging preclinical placebo analgesia models and clinical neuroscience at the Brain and Mind Centre, this shift establishes a validated molecular framework for patient stratification and treatment monitoring that will be essential as disease-modifying therapies move into routine care.
Novelty
78%
Rigor
85%
Significance
92%
Validity
83%
Clarity
90%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
